SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

November 2019 Autoimmune News

Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials)

Clinical evaluation of total and high-avidity (HA) anti-dsDNA antibody assays (EIA) for the diagnosis of systemic lupus erythematosus (SLE). The HA anti-dsDNA EIA kit in association with the total anti-dsDNA kit provided superior performance in SLE diagnosis and monitoring disease activity. PubMed, Lupus, 09/30/2019. (Also see Diagnosis of Lupus)

Risk factors associated with IgA vasculitis with nephritis (VN) (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. This meta-analysis showed that older age at onset, lower GFR, initial renal features and renal biopsy with crescentic nephritis were predictive of poor prognosis in children with IgA-VN. PubMed, PLoS One, 2019 Oct 1;14(10):e0223218. (Also see Vasculitis)

Effects of Sarilumab on Rheumatoid Arthritis (RA) as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease (RAID) Scale. Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients' lives to a greater extent than placebo + csDMARD or adalimumab monotherapy. PubMed, J Rheumatol, 2019 Oct;46(10):1259-1267. (Also see Treatments for Rheumatoid Arthritis)

Ultrasensitive serum interferon-α quantification during systemic lupus erythematosus (SLE) remission identifies patients at risk for relapse. Direct serum IFN-α assessment with highly sensitive digital immunoassay permits clinicians to identify a subgroup of SLE patients, clinically in remission, but at higher risk of relapse. PubMed, Ann Rheum Dis, 09/30/2019. (Also see Systemic Lupus Erythematosus)

Prevalence of Antiphospholipid Antibodies (aPL) Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. aPL negativisation occurred in approximately 9% of patients and negativisation occurred most often in patients who were previously found to be positive for only one aPL. PubMed, Thromb Haemost, 10/06/2019. (Also see Antiphospholipid Syndrome)

Treatment Failures of Direct Oral Anticoagulants (DOACs). Our analysis illustrates that DOACs may fail in the setting of Food and Drug Administration and non-Food and Drug Administration- approved indications. PubMed, Am J Ther, 10/09/2019. (Also see Antiphospholipid Syndrome)

Celiac Disease (CD) and the Microbiome. This review is aimed at summarizing both pre-clinical and clinical evidence addressing the relationship between the intestinal microbiome and CD. PubMed, Nutrients, 2019 Oct 8;11(10). (Also see Celiac Disease)

Type 1 Diabetes Mellitus (T1D) and Celiac Disease (CD): Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms. Immunogenetics and the environment are closely interrelated in the pathogenesis of T1D and CD. PubMed, Horm Res Paediatr, 2019 Oct 8:1-8. (Also see Celiac Disease and Symptoms and Complications of Diabetes)

Glycemic variability indices can be used to diagnose islet transplantation (IT) success in type 1 diabetic patients. The proposed thresholds allow an easy evaluation of IT success using only continuous glucose monitoring data and may be a clinical tool for the follow-up of transplanted patients. PubMed, Acta Diabetol, 10/10/2019. (Also see Treatments for Diabetes)

Go to Autoimmune News: October 2019

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.